I do not beleive any questions to a takeover offer are warrented, you cross that bridge when it comes. It can prove a distraction from the areas that are actually in managements circle of influence and area of control.
In my opinion potential questions could be:
The Chairman Rob Thomas in the2017 annual report stated "In terms of the year ahead, Starpharma ison thecusp of several near term catalysts: commercialisationof its VivaGel® BV products; commencement and progress of clinical trials formultiple DEP® candidates; and more DEP®partnerships. Since wewere on the cusp of more DEP partnerships in Aug 2017 and more than 12 monthshas passed. Can you provide an updateabout why a delay has occurred in not signing on more partnerships or what youmeant about being on the cusp of more DEP partnerships in the 2017 annualreport.
Can you provide an update on the delay to the clinic of AZD0466? Astranenica in their IMED 2017 annual report indicated it would be in the clinic in 2017/2018.
As Christmas is a large sales cycle in Australia, do you expect ASPEN Pharmacare to launch Fleurstat by the end of 2018?
When the chairmen mentioned in the 2018 annual report that DEP Irinotecan is targeted for phase 1 trials by the end of the year did he mean calendar year or financial year? In future can you ensure that communication lines to shareholders does not require assumptions to be made?
In the recent presentation to Citic it was indicated the US Vivagel Distribution partnership was expected prior to the FDA decision. Can you provide at this point a further update regarding the progress and expected completion of partnership negotiations?
Has Starpharma been contacted by the FDA with any concerns regarding the application within 2018? Do you remain of the view that the FDA decision is due approximately 6 months from when it was accepted?
